| Literature DB >> 26456833 |
Sonia Mulero-Navarro1, Ana Sevilla2, Angel C Roman3, Dung-Fang Lee2, Sunita L D'Souza2, Sherly Pardo4, Ilan Riess5, Jie Su2, Ninette Cohen6, Christoph Schaniel7, Nelson A Rodriguez8, Alessia Baccarini6, Brian D Brown6, Hélène Cavé9, Aurélie Caye9, Marion Strullu9, Safak Yalcin10, Christopher Y Park10, Perundurai S Dhandapany8, Ge Yongchao11, Lisa Edelmann6, Sawsan Bahieg6, Patrick Raynal12, Elisabetta Flex13, Marco Tartaglia14, Kateri A Moore2, Ihor R Lemischka7, Bruce D Gelb15.
Abstract
Somatic PTPN11 mutations cause juvenile myelomonocytic leukemia (JMML). Germline PTPN11 defects cause Noonan syndrome (NS), and specific inherited mutations cause NS/JMML. Here, we report that hematopoietic cells differentiated from human induced pluripotent stem cells (hiPSCs) harboring NS/JMML-causing PTPN11 mutations recapitulated JMML features. hiPSC-derived NS/JMML myeloid cells exhibited increased signaling through STAT5 and upregulation of miR-223 and miR-15a. Similarly, miR-223 and miR-15a were upregulated in 11/19 JMML bone marrow mononuclear cells harboring PTPN11 mutations, but not those without PTPN11 defects. Reducing miR-223's function in NS/JMML hiPSCs normalized myelogenesis. MicroRNA target gene expression levels were reduced in hiPSC-derived myeloid cells as well as in JMML cells with PTPN11 mutations. Thus, studying an inherited human cancer syndrome with hiPSCs illuminated early oncogenesis prior to the accumulation of secondary genomic alterations, enabling us to discover microRNA dysregulation, establishing a genotype-phenotype association for JMML and providing therapeutic targets.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26456833 PMCID: PMC4618050 DOI: 10.1016/j.celrep.2015.09.019
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423